Appraisal of patient-level health economic models of severe mental illness: systematic review
Open Access
- 19 August 2021
- journal article
- review article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 220 (2) , 86-97
Abstract
Background: Healthcare decision makers require accurate long-term economic models to evaluate the cost-effectiveness of new mental health interventions.Aims: To assess the suitability of current patient-level economic models to estimate long-term economic outcomes in severe mental illness.Method: We undertook pre-specified systematic searches in MEDLINE, Embase and PsycINFO to identify reviews and stand-alone publications of economic models of interventions for schizophrenia, bipolar disorder and major depressive disorder (PROSPERO: CRD42020158243). We screened paper titles and abstracts to identify unique patient-level economic models. We conducted a structured extraction of identified models, recording the presence of key predefined model features. Model quality and validation were appraised using the 2014 ISPOR and 2016 AdViSHE model checklists.Results: We identified 15 unique patient-level models for psychosis and major depressive disorder from 1481 non-duplicate records. Models addressed schizophrenia (n= 6), bipolar disorder (n= 2) and major depressive disorder (n= 7). The predominant model type was discrete event simulation (n= 9). Model complexity and incorporation of patient heterogeneity varied considerably, and only five models extrapolated costs and outcomes over a lifetime horizon. Key model parameters were often based on low-quality evidence, and checklist quality assessment revealed weak model verification procedures.Conclusions: Existing patient-level economic models of interventions for severe mental illness have considerable limitations. New modelling efforts must be supplemented by the generation of good-quality, contemporary evidence suitable for model building. Combined effort across the research community is required to build and validate economic extrapolation models suitable for accurately assessing the long-term value of new interventions from short-term clinical trial data.Keywords
Funding Information
- National Institute for Health Research (i4i programme (Project II-C7-0117-20001))
- Wellcome (102176/B/13/Z)
This publication has 74 references indexed in Scilit:
- Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health communityBMC Health Services Research, 2013
- Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational studyAnnals of General Psychiatry, 2013
- Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive EpisodePharmacoEconomics, 2012
- Functional Impairment and Disability across Mood States in Bipolar DisorderValue in Health, 2010
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United StatesCost Effectiveness and Resource Allocation, 2009
- Serious mental illness and physical health problems: A discussion paperInternational Journal of Nursing Studies, 2007
- A taxonomy of model structures for economic evaluation of health technologiesHealth Economics, 2006
- Model to assess the cost-effectiveness of new treatments for depressionInternational Journal of Technology Assessment in Health Care, 2006
- Quality-of-Life Impairment in Depressive and Anxiety DisordersAmerican Journal of Psychiatry, 2005